NVAX and SVA swine flu vaccines are effective

Shares of NVAX and SVA rose approximately 10% this morning on positive results of their respective swine flu vaccines. NVAX's VLP vaccine immunized ferrets from the flu, while the SVA egg-based vaccine displayed immunogenicity among humans.

http://www.reuters.com/article/marketsNews/idINN1834168720090818?rpc=44

NVAX has multiple partnership agreements with India's Cadila and Spain's Rovi to manufacture the VLP vaccine for Asian, European, and Latin American countries. NVAX is also working with the NIH and FDA in clinical-stage trials in the US.

SVA has an order for a minimum of 10 million doses to cover Beijing, but will likely garner additional orders for domestic Chinese provinces as well as other Asian countries, including a distribution deal for the Philippines.